Please use this identifier to cite or link to this item:
|Title:||p63 is useful in the diagnosis of mammary metaplastic carcinomas|
|Citation:||Tse, G.M., Tan, P.-H., Chaiwun, B., Puttis, T.C., Lui, P.C.W., Tsang, A.K.H., Wong, F.C.L., Lo, A.W.I. (2006-02). p63 is useful in the diagnosis of mammary metaplastic carcinomas. Pathology 38 (1) : 16-20. ScholarBank@NUS Repository. https://doi.org/10.1080/00313020500444625|
|Abstract:||Aims: p63 has been recently reported to be expressed in sarcomatoid/metaplastic carcinoma of the breast, in addition to its role as a myoepithelial marker. A large series of 34 metaplastic carcinomas, including cases with pure epithelial component (squamous cell and adenosquamous carcinomas), biphasic tumours with carcinomatous and sarcomatoid components and monophasic tumours with only spindle cell component, were evaluated for p63 expression with respect to the different cellular components. Methods: All of the metaplastic carcinomas were assessed for p63 and conventional epithelial and mesenchymal markers of AE1/3, CAM5.2 and vimentin by immunohistochemistry. Results: All of the different categories of metaplastic carcinomas showed similar clinico-pathological features (patient age, tumour size, nuclear grade, mitotic activity, lymph node status and hormonal receptor status). For metaplastic carcinoma with epithelial component only, p63 was only expressed in the squamous cell component, but not the adenocarcinoma component. Eight of the 10 tumours were positive for p63. For the tumours with sarcomatoid component, either singly or together with carcinomatous component, p63 was positive in 14 of 24 cases. Pure sarcomas and carcinomas were all negative for p63 staining by immunohistochemistry, thus rendering p63 staining highly specific for diagnosing metaplastic carcinoma. Conclusions: Using p63 for diagnosis of metaplastic carcinoma gives a sensitivity of 65%, a specificity of 96%, a positive predictive value of 96%, and a negative predictive value of 66% and an accuracy of 78%. p63 may be used as an adjunct marker in the diagnosis of metaplastic carcinoma. © 2006 Royal College of Pathologists of Australasia.|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
checked on Jan 15, 2019
WEB OF SCIENCETM
checked on Jan 15, 2019
checked on Feb 26, 2018
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.